OOIR: Observatory of International Research

Papers

(The TQCC of Trends in Pharmacological Sciences is 17. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)

Article	Citations
Subscription and Copyright Information	791
Subscription and Copyright Information	510
Ensifentrine (Ohtuvayre™) for chronic obstructive pulmonary disease	354
Subscription and Copyright Information	204
Subscription and Copyright Information	195
Advisory Board and Contents	180
Subscription and Copyright Information	168
DOT1L: orchestrating methylation-dependent radiotheRAPy responses via BRCA1	152
Muscarinic receptors: from clinic to bench to clinic	146
Assembling the P450 puzzle: on the sources of nonadditivity in drug metabolism	142
Monitoring neurodegeneration through brain-derived extracellular vesicles in biofluids	131
Advancing chemical carcinogenicity prediction modeling: opportunities and challenges	126
Structural asymmetry in FGF23 signaling	119
Targeting complement in neurodegeneration: challenges, risks, and strategies	114
Swinging the SWI/SNF complexes for cancer therapy	112
Compstatins: the dawn of clinical C3-targeted complement inhibition	109
Structural pharmacology and mechanisms of GLP-1R signaling	104
Peptides as a therapeutic strategy against Klebsiella pneumoniae	103
Direct in vivo CAR T cell engineering	96
Shearing of surface mucin saps tumor cell strength	96
Therapeutic inhibition of ferroptosis in neurodegenerative disease	96
Advisory Board and Contents	94
Advisory Board and Contents	85
Chemically modified neoantigen-based immunotherapy for targeting KRASG12C-driven tumors	84
Phenotypic approaches for CNS drugs	80

Emerging strategies for beta cell transplantation to treat diabetes	78
Nemolizumab (Nemluvio®) for prurigo nodularis	78
Liquid–liquid phase separation: a principal organizer of the cell’s biochemical activity architecture	75
Ribosome-directed cancer therapies: the tip of the iceberg?	75
A smart hospital-driven approach to precision pharmacovigilance	70
HSV-1 as a gene delivery platform for cancer gene therapy	70
Advisory Board and Contents	68
A deep dive into degrader-induced protein-protein interfaces	67
Engineering ACE2 decoy receptors to combat viral escapability	66
Optogenetic engineering for precision cancer immunotherapy	66
Leveraging human microbiomes for disease prediction and treatment	66
Mechanistic considerations for adenosine-lidocaine-magnesium (ALM) in controlling coagulopathy	65
A perspective on psychedelic teratogenicity: the utility of zebrafish models	63
siRNA drug Leqvio (inclisiran) to lower cholesterol	62
Genetically engineered loaded extracellular vesicles for drug delivery	61
Advisory Board and Contents	61
Suzetrigine for moderate to severe acute pain	60
Close to a year in TIPS’ saddle – I am optimistic	58
Subscription and Copyright Information	58
Thriving as members of under-represented groups in pharmacology-related careers	57
GPR35, ally of the anti-ischemic ATPIF1-ATP synthase interaction	54
Emerging approaches to induce immune tolerance to therapeutic proteins	53
Piezo1: structural pharmacology and mechanotransduction mechanisms	50
The structure, function, and pharmacology of MRGPRs	50
Could dexmedetomidine be repurposed as a glymphatic enhancer?	49
Subscription and Copyright Information	49
Selective tyrosine kinase 2 inhibitors in inflammatory bowel disease	48
Mentoring future science leaders to thrive	47
Alzheimer’s therapeutic development: shifting neurodegeneration to neuroregeneration	47
Targeting AMPK as a potential treatment for hepatic fibrosis in MASLD	46
Advisory Board and Contents	43
Advancing non-destructive analysis of 3D printed medicines	43
The promise of targeted protein degradation approaches	43
Lipoxygenases in chronic liver diseases: current insights and future perspectives	43
Hepatic mitochondrial reductive stress in the pathogenesis and treatment of steatotic liver disease	42
The road less traveled: activating an oncogenic kinase	42
Targeting LKB1/STK11-mutant cancer: distinct metabolism, microenvironment, and therapeutic resistance	42
Salt-inducible kinases: new players in pulmonary arterial hypertension?	42
Mavacamten improves symptoms in obstructive hypertrophic cardiomyopathy patients	42
Promising neuroimmune targets and drugs for CNS diseases	41
Inhalable neutralizing antibodies – promising approach to combating respiratory viral infections	41
Advisory Board and Contents	40
Subscription and Copyright Information	40
A novel function of the M2 muscarinic receptor	38
Protein acylations in cancer immunity: effects and therapeutic opportunities	36
The end of the beginning in understanding SLC22 polyspecificity	36
Monkeypox: potential vaccine development strategies	36
Validation of agent-based models of surface receptor oligomerisation	35
Nanocarriers for oral delivery of biologics: small carriers for big payloads	35
Frizzleds act as dynamic pharmacological entities	35

Targeting intracellular protein–protein interactions with macrocyclic peptides	35
Beyond G protein and arrestin: GRK2-biased β₂AR signaling	32
Advisory Board and Contents	32
Decoding pseudouridine: an emerging target for therapeutic development	32
BTK inhibitors: past, present, and future	32
Metabolic regulation in normal and leukemic stem cells	31
SEAKER cells coordinate cellular immunotherapy with localized chemotherapy	30
Histone lysine acetyltransferase inhibitors: an emerging class of drugs for cancer therapy	30
Circulating tumor cells in precision medicine: challenges and opportunities	30
Demographic diversity in platelet function and response to antiplatelet therapy	30
Voltage-gated ion channels in epilepsies: circuit dysfunctions and treatments	29
Recent advances in generative biology for biotherapeutic discovery	29
Neurofilament light chain as a biomarker of chemotherapy-induced peripheral neuropathy	29
Eflornithine for treatment of high-risk neuroblastoma	29
Development of PROTACs using computational approaches	28
Host-directed therapies for tuberculosis: quantitative systems pharmacology approaches	28
Engineered antibody fusion proteins for targeted disease therapy	28
Subscription and Copyright Information	28
GPR35: from enigma to therapeutic target	28
Biologics and cardiac disease: challenges and opportunities	27
Subscription and Copyright Information	27
Subscription and Copyright Information	27
High-power screening (HPS) empowered by DNA-encoded libraries	27
A novel anticancer pharmacological agent targeting mitochondrial complex I	27
Harnessing associative learning paradigms to optimize drug treatment	27
Magnesium for disease treatment and prevention: emerging mechanisms and opportunities	27
Tackling chronic kidney disease in diabetic patients with finerenone	27
Targeting plasma membrane cholesterol as a novel anticancer therapy	26
Targeting sensory neuron GPCRs for peripheral neuropathic pain	25
Oteseconazole (VIVOJA) for prevention of recurrent vulvovaginal candidiasis	25
Neutrophil extracellular traps in wound healing	25
Challenges and opportunities associated with rare-variant pharmacogenomics	24
Subscription and Copyright Information	24
Modulation of Wnt–β-catenin signaling with antibodies: therapeutic opportunities and challenges	24
Crosstalk between androgen receptor and protein kinase G signaling in bone: implications for osteoporosis therapy	24
Visceral obesity and HFpEF: targets and therapeutic opportunities	24
Taming PRMT5–adaptor protein interactions	24
Recent advancements in vaccine research and development	24
Boosting CAR-T cell therapy through vaccine synergy	24
GABAA receptors as targets for treating affective and cognitive symptoms of depression	23
Targeting methionine aminopeptidase 2 in cancer, obesity, and autoimmunity	23
Circadian biology to advance therapeutics for mood disorders	23
Emerging strategies for engineering Escherichia coli Nissle 1917-based therapeutics	22
Advisory Board and Contents	22
The ABCs of psychedelics: a preclinical roadmap for drug discovery	22
NLRP3 and pyroptosis blockers for treating inflammatory diseases	22
Harnessing UBR5 for targeted protein degradation of key transcriptional regulators	21
GPCR-dependent and -independent arrestin signaling	21
Subscription and Copyright Information	21
Potential for targeting small heat shock protein modifications	21
Advisory Board and Contents	20
Odorant receptors as potential drug targets	20
Targeted protein degrader development for cancer: advances, challenges, and opportunities	20
Glymphatic-stagnated edema induced by traumatic brain injury	20
The structure and function of YTHDF epitranscriptomic m6A readers	20
Advisory Board and Contents	19
Hans Jürg Schatzmann (1924–2021)	19
Subscription and Copyright Information	18
Bridging the gap in neuropsychiatric translational research	18
Thapsigargin: key to new host-directed coronavirus antivirals?	18
Harnessing deep learning for enhanced ligand docking	18
KRASG12C/mTORC1 inhibition: a powerful duo in NSCLC therapeutics	18
Learning from natural design for local anesthetic delivery	17
Advancing small-molecule drug discovery by encoded dual-display technologies	17
Leveraging non-enzymatic functions of LSD1 for novel therapeutics	17
Glaucoma: neuroprotection with NAD-based therapeutic interventions	17
Malolactone strikes: K-Ras-G12D's Achilles' heel	17
Emerging epigenetic insights into aging mechanisms and interventions	17